Skip to content
OpenCapital
Get started

Perrigo Company PRGO Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Abbott logo
AbbottABT
$1.2B+53.1%
Coty logo
CotyCOTY
——
Edgewell Personal Care logo
Edgewell Personal CareEPC
——

Other financials

Income statement

See full
Revenue$969.2M-7.2%
Gross profit$325.5M-17.0%
Operating income-$372.3M-894%
Net income-$398.6M-6,128%
EPS (diluted)-$2.87-5,640%

Balance sheet

See full
Cash & equivalents$357.2M-12.9%
Total debt$3.8B-0.6%
Total equity$2.5B-42.7%
Total assets$8.0B-18.2%

Cash flow

See full
Operating cash flow-$113.6M-76.1%
CapEx$13.8M-45.9%
Free cash flow-$127.4M-41.6%

Valuation

See full
Market cap$1.35B-61.4%
Enterprise value$4.82B-31.9%
P/S0.3×-0.5×

Profitability

See full
Gross margin34.2%-2.2pp
Operating margin-36.9%-41.8pp
Net margin-43.5%-48.6pp
FCF margin4.2%-2.0pp

Returns & leverage

See full
Return on equity-53%-57.7pp
Debt / equity1.5×+0.6×
Current ratio2.7×+0.4×

Where this comes from

Reported directly by Perrigo Company in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Perrigo Company’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perrigo Company's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perrigo Company's indefinite-lived research and development assets?
Perrigo Company (PRGO) reported indefinite-lived research and development assets of $4.6M in Q1 2026.
How has Perrigo Company's indefinite-lived research and development assets changed year-over-year?
Perrigo Company's indefinite-lived research and development assets decreased by 13.2% year-over-year, from $5.3M to $4.6M.
What is the long-term trend for Perrigo Company's indefinite-lived research and development assets?
Over 5 years (2020 to 2025), Perrigo Company's indefinite-lived research and development assets has grown at a -8.1% compound annual growth rate (CAGR), from $7M to $4.6M.